Copenhagen Oe

• This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab … Ended recruitment
  2023-509276-42-00 6 2019-10-30 Children and Adolescents with Cancers Harboring V600 mutation.
• Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors Ended recruitment
  2023-503425-18-00 1 2019-10-02 Metastatic Solid Tumors
• GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended recruitment
  2023-508526-10-00 7 2019-10-01 Malignant solid tumors: Patients with relapsed or refractory, advanced
• Treatment Of Metastatic Bladder cancer at the time Of biochemical reLApse following radical cystectomy - TOMBOLA Ended recruitment
  2024-510865-41-00 6 2019-09-26 Urothelial cancer
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel … Ended recruitment
  2023-505219-19-00 9 2019-09-03 Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l … Ended recruitment
  2022-502616-37-00 9 2019-07-30 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
• EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended recruitment
  2023-508478-27-00 4 2019-07-30 Advanced stage Hodgkin Lymphoma
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto … Ended recruitment
  2023-504932-16-00 5 2019-06-04 Muscle Invasive Bladder Cancer
• An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens … Ended recruitment
  2023-509305-68-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients Ended recruitment
  2023-508081-15-00 4 2019-04-04 High-risk B-cell acute lymphoblastic leukemia
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre … Ended recruitment
  2023-509349-11-00 5 2019-03-22 Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended recruitment
  2023-506777-36-00 10 2019-01-04 Prostate Cancer
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood Ended recruitment
  2023-510009-16-00 9 2018-12-04 Acute Myeloid Leukemia
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM … Ended recruitment
  2024-517417-32-00 4 2018-11-22 CHRONIC MYELOID LEUKEMIA
• A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small- … Ended recruitment
  2024-515755-37-00 4 2018-07-31 Limited disease small-cell lung cancer
• Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in pati … Ended recruitment
  2023-508551-40-00 6 2018-06-08 Coronary artery multi-vessel disease and left main stenosis
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended recruitment
  2023-504802-12-00 7 2018-05-16 Lymphoma of B-cell origin
• A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patient … Ended recruitment
  2023-505222-34-00 7 2018-04-23 Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
• A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First- … Ended recruitment
  2023-503469-49-00 5 2018-04-19 Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
• RAM-MS Ended recruitment
  2024-510630-40-00 5 2018-02-12 Multiple sclerosis
• Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bor … Ended recruitment
  2023-506110-43-00 9 2018-01-25 Multiple Myeloma
• ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended recruitment
  2024-514275-18-00 10 2017-12-06 Mantle Cell Lymphoma (MCL)

Showing 505–528 of 671 trials